EGFR and non-small cell lung carcinoma: Icotinib (BPI-2009H) is a specific small-molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which has shown clinical anticancer activity in patients with advanced NSCLC [15].